Alembic Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Alembic Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹89Over the last 3 years, every ₹100 of reported profit came with ₹89 of operating cash.
Lower than 60% of Healthcare companies in India.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Lower than 56% of Healthcare companies in India.
Cash Locked Ratio
₹40For every ₹100 of sales, ₹40 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹31 tied up three years earlier.
More money tied up than 77% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹19Sales grew 31% in 3 years; of every extra ₹100 of sales, ₹19 became extra profit.
Higher than 57% of Healthcare companies in India.
Asset Productivity Ratio
+31% / +42%In 3 years sales changed by +31% while total assets changed by +42%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.6×Debt due within a year is covered 0.6 times by its yearly operating cash.
Lower than 67% of Healthcare companies in India.
Cash Cushion Ratio
−8%Debt, after subtracting cash, equals 8% of its market value (net debt).
Lower than 74% of Healthcare companies in India.
Tangible Assets Ratio
97%Of every ₹100 the company owns, ₹97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 52% of Healthcare companies in India.
Tangible Net Worth Ratio
95%Of every ₹100 of net worth, ₹95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 51% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Alembic Pharmaceuticals Limited owes ₹0.35 for every ₹1 it owns. Net profit rose 16% in the year to Mar 2026, and grew 25% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
21.6Investors pay ₹21.6 for every ₹1 of Alembic Pharmaceuticals Limited's yearly profit, lower than 79% of Healthcare companies in India.
P/B ratio
2.63The share price is 2.63 times Alembic Pharmaceuticals Limited's book value per share, lower than 75% of Healthcare companies in India.
Market cap
₹14,941 CrThe total market value of all of Alembic Pharmaceuticals Limited's shares at today's price (share price × number of shares), larger than 72% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹5,675 CrWhat Alembic Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹288.70Net worth divided by the number of shares. The share price of ₹760.10 is 2.6 times this, which is the P/B above.
Return on equity (ROE)
12.2%Alembic Pharmaceuticals Limited earned 12.2% on its shareholders' money over the last year, lower than 54% of Healthcare companies in India.
Owes vs Owns
0.35×Alembic Pharmaceuticals Limited owes ₹0.35 for every ₹1 it owns (low), lower than 56% of Healthcare companies in India.
Dividend yield
1.50%Alembic Pharmaceuticals Limited pays 1.50% of its share price as dividends a year, higher than 88% of dividend-paying Healthcare companies in India.
Revenue growth
+10%Revenue rose 10% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Profit growth
+16%Net profit rose 16% in the year to Mar 2026, and grew 25% a year on average over 3 years.
Profit margin
9.4%Alembic Pharmaceuticals Limited keeps ₹9 of every ₹100 of revenue as net profit.
Cash quality
1.2×Cash from Alembic Pharmaceuticals Limited's business was 1.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
8.6×Alembic Pharmaceuticals Limited's operating profit covered its interest costs 8.6 times in the year to Mar 2026.
Cash vs debt
Net debtAlembic Pharmaceuticals Limited had ₹1,234 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Alembic Pharmaceuticals Limited's P/E ratio?
Investors pay ₹21.6 for every ₹1 of Alembic Pharmaceuticals Limited's yearly profit, lower than 79% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Alembic Pharmaceuticals Limited: ₹14,941 Cr ÷ ₹5,675 Cr (31 Mar 2026) = 2.6.
What is Alembic Pharmaceuticals Limited's return on equity?
Alembic Pharmaceuticals Limited earned 12.2% on its shareholders' money over the last year, lower than 54% of Healthcare companies in India.
How much does Alembic Pharmaceuticals Limited owe compared with what it owns?
Alembic Pharmaceuticals Limited owes ₹0.35 for every ₹1 it owns (low), lower than 56% of Healthcare companies in India.
Does Alembic Pharmaceuticals Limited pay a dividend?
Yes. Alembic Pharmaceuticals Limited pays 1.50% of its share price as dividends a year, higher than 88% of dividend-paying Healthcare companies in India.
Is Alembic Pharmaceuticals Limited's revenue growing?
Revenue rose 10% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.